The Big 3

Digital technology, AI and other tools will allow for many specialty infusion therapies to be administered in ambulatory centers, allowing payers to customize programs.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

The Type 1 Diabetes Grand Challenge has provided awards to six universities —including three in the United States — to fund research of novel therapies to treat patients with type 1 diabetes.

In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.

The IQVIA vice president and frequent speaker at pharmacy and managed care meetings said he will retire in May 2025.

The private-label biosimilar will be available at an 80% discount off Stelara. Evernorth has not released information about which company will be producing the biosimilar.